> Details

Solana-Altabella, Antonio; Megías-Vericat, Juan Eduardo; Ballesta-López, Octavio; Boluda, Blanca; Cano, Isabel; Acuña-Cruz, Evelyn; Rodríguez-Veiga, Rebeca; Torres-Miñana, Laura; Sargas, Claudia; Sanz, Miguel Á.; Borrell-García, Carmela; López-Briz, Eduardo; Poveda-Andrés, José Luis; De la Rubia, Javier; Montesinos, Pau; Martínez-Cuadrón, David

Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
  • Contributor: Solana-Altabella, Antonio; Megías-Vericat, Juan Eduardo; Ballesta-López, Octavio; Boluda, Blanca; Cano, Isabel; Acuña-Cruz, Evelyn; Rodríguez-Veiga, Rebeca; Torres-Miñana, Laura; Sargas, Claudia; Sanz, Miguel Á.; Borrell-García, Carmela; López-Briz, Eduardo; Poveda-Andrés, José Luis; De la Rubia, Javier; Montesinos, Pau; Martínez-Cuadrón, David
  • Published: MDPI AG, 2022
  • Published in: Cancers, 14 (2022) 8, Seite 1921
  • Language: English
  • DOI: 10.3390/cancers14081921
  • ISSN: 2072-6694
  • Origination:
  • Footnote:
  • Description: Background: Information regarding the impact on healthcare systems of secondary acute myeloid leukemia (sAML) is scarce. Methods: A retrospective review of medical charts identified patients aged 60–75 years with sAML between 2010 and 2019. Patient information was collected from diagnosis to death or last follow-up. Outpatient resource use, reimbursement, frequency and duration of hospitalization, and transfusion burden were assessed. Forty-six patients with a median age of 64 years were included. Anthracycline plus cytarabine regimens were the most common induction treatment (39 patients, 85%). The ratio of the total days hospitalized between the total follow-up was 29%, with a sum of 204 hospitalizations (average four/patient; average duration 21 days). The total average reimbursement was EUR 90,008 per patient, with the majority (EUR 77,827) related to hospital admissions (EUR 17,403/hospitalization). Most hospitalizations (163, mean 22 days) occurred in the period before the first allogeneic hematopoietic stem cell transplant (alloHSCT), costing EUR 59,698 per patient and EUR 15,857 per hospitalization. The period after alloHSCT (in only 10 patients) had 41 hospitalizations (mean 21 days), and a mean reimbursement cost of EUR 99,542 per patient and EUR 24,278 per hospitalization. In conclusion, there is a high consumption of economic and healthcare resources in elderly patients with sAML receiving active treatments in Spain.
  • Access State: Open Access